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Abstract
Introduction—Young women with breast cancer face treatments that impair ovarian function,
but it is not known if malignancy itself impacts ovarian reserve. As more breast cancer patients
consider future fertility, it is important to determine if ovarian reserve is impacted by cancer, prior
to any therapeutic intervention.
Methods—A cross-sectional study was conducted comparing if ovarian reserve, as measured by
anti-mullerian hormone (AMH), follicle stimulating hormone (FSH) and inhibin B (inhB), differed
between 108 women with newly diagnosed breast cancer and 99 healthy women without breast
cancer. Breast cancer participants were ages 28–44 and were recruited from two clinical breast
programs. Healthy women ages 30–44 without a history of infertility were recruited from
gynecology clinics and the community.
Results—The median age (interquartile range) was 40.2(5.5) years for breast cancer participants
and 33.0(4.6) years for healthy controls. The unadjusted geometric mean AMH levels (SD) for
breast cancer participants and controls were 0.66(3.6) ng/mL and 1.1(2.9) ng/mL, respectively.
Adjusting for age, body mass index, gravidity, race, menstrual pattern and smoking, mean AMH
levels were not significantly different between breast cancer participants and healthy controls
(0.85 vs. 0.76 ng/mL, p=0.60). FSH and inhB levels did not differ by breast cancer status. In
exploratory analysis, the association between AMH and breast cancer status differed by age (p-
interaction=0.02). AMH may be lower with breast cancer status in women older than 37. In
younger women, AMH levels did not differ significantly by breast cancer status.
Conclusions—Among the youngest of breast cancer patients, ovarian reserve as measured by
AMH, FSH and inhibin B did not differ significantly from healthy women of similar age. In older
breast cancer patients, ovarian reserve may be adversely impacted by cancer status. These findings
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support the potential success and need for fertility preservation strategies prior to institution of
cancer treatment.
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Introduction
Breast cancer is the leading cause of cancer in young women, accounting for 25% of cases
diagnosed by age 40 [1]. At diagnosis, young breast cancer patients face a myriad of
challenges, including decisions on preserving fertility prior to cancer treatment. It is well-
established that chemotherapy used to treat breast cancer incurs damage to the ovarian
reserve, or the quantity and quality of remaining oocytes [2–4], resulting in loss of fertility
and premature ovarian failure [5, 6]. However, it is not known whether malignancy itself
impacts ovarian reserve.
In young men who are newly diagnosed with certain types of cancer, semen parameters may
be decreased prior to any gonadotoxic treatment [7, 8], suggesting an independent effect of
malignancy on reproductive potential. As more female breast cancer patients consider future
fertility, it is important to determine if ovarian reserve is impacted by cancer, prior to any
therapeutic intervention. This will allow us to better understand the interplay between cancer
and ovarian function as well as guide stimulation for egg or embryo banking.
Ovarian reserve is measured by hormone and ultrasound biomarkers, including anti-
Mullerian hormone (AMH), follicle stimulating hormone (FSH), inhibin B (inhB) and antral
follicle count (AFC) [9–12]. Among these measures, AMH is a good candidate biomarker
because it is relatively stable across the menstrual cycle and has been associated with
reproductive outcomes from time to menopause to assisted reproduction (ART) responses in
normal and infertile women [13, 14].
In young women with cancer, several studies compared ovarian reserve markers and ovarian
stimulation outcomes between cancer patients and infertile controls [15–19]. These studies
reported mixed results and are limited by the heterogeneity of cancer diagnoses and use of
infertile women as the control population. Therefore, the objective of this study was to test if
hormone measures of ovarian reserve differ between young breast cancer patients and
healthy women without a history of infertility. We hypothesized that AMH levels in young
breast cancer patients would be lower than AMH in healthy women.
Methods
We performed a cross-sectional study to determine if AMH, FSH, and inhB levels differ in
young women with and without breast cancer. Participants were ages 28 to 44,
premenopausal (defined as having at least one period within the past year), and had no
history of gonadotoxic therapy or oophorectomy. Breast cancer participants were recruited
from breast oncology clinics at the University of Pennsylvania and the University of
California, San Diego, diagnosed with an in situ or invasive cancer between 2008 and 2011,
and enrolled within 4 months of cancer diagnosis, prior to any systemic cancer treatment.
Healthy controls were participants of an ongoing study on ovarian aging and fecundability
and recruited at the University of North Carolina, Chapel Hill, between 2008 and 2011
through general clinics, emails to University faculty and staff, and flyers and informational
letters for the community. By screening questionnaires at enrollment, control participants
did not have a diagnosis of breast cancer. The cohort study of breast cancer patients was
approved by the institutional review boards (IRB) of the University of California San Diego
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and University of Pennsylvania; the cohort study of healthy participants was approved by
the IRB of University of North Carolina.
Breast cancer participants underwent a blood draw prior to start of systemic cancer therapy.
With a limited time window prior to start of cancer treatment, blood draws were not timed to
occur in the early follicular phase. Healthy participants provided early follicular phase
(menstrual cycle day 2, 3, or 4) serum. Sera were extracted from all samples and frozen at
−80C. Clinical data were abstracted from medical records and self-reported questionnaires.
Study samples were assayed for AMH, FSH, inhB and estradiol at the University of
Southern California Reproductive Endocrine Research Laboratory. AMH was measured by
the AMH enzyme-linked immunosorbent assay kits (Beckman Coulter, AMH Gen II assay,
Brea, CA, USA). The limit of detectability was 0.17 ng/mL. The inter-assay coefficient of
variability (CV) was 4.8%. FSH was measured by a direct immunochemiluminometric assay
using the automated Immulite system. The limit of detectability was 1.0 IU/L and inter-
assay CV was 5.0%. Estradiol was measured by radioimmunoassay after an organic solvent
extraction step. The limit of detectability was 0.49 pg/mL and inter-assay CV was 13.7%.
InhB assays used a monoclonal two site enzyme-linked immunosorbent assay. The limit of
detectability was 9.4 pg/mL and inter-assay CV was 1.5%. Values below detection
thresholds were given half of the threshold value in analyses.
Analyses were conducted using Stata software (Release 12, College Station, TX) and R
freeware (Version 2.14.1, R Foundation for Statistical Computing, Vienna, Austria).
Graphic displays of continuous variables were explored to determine data distributions.
Hormone levels were transformed to natural log values to minimize the impact of skewed
distributions. Transformed hormone measures were observed to have a Gaussian
distribution. Continuous variables were summarized by means (standard deviation [SD]) or
medians (interquartile range [IQR]), and compared by breast cancer status using the
Student’s t-test or Wilcoxon ranksum test, as appropriate. Categorical variables were
characterized as proportions and compared using chi-squared or exact methods, as
appropriate. Linear regression methods were used to model the association between log-
transformed hormone levels and cancer status while adjusting for potential confounding by
age, cancer status and demographic variables. Variables with p<0.1 based on the Wald test
for univariate associations and known confounders from prior data [20] were included in the
multivariate models. Analysis of FSH and inhB were restricted to participants with an
estradiol of <80 pg/mL to approximate for the early follicular phase. To explore the
hypothesis of potential effect modification by age, we examined the interaction between age
and breast cancer status by including the product of these 2 variables in the model. Since this
interaction was significant, we conducted additional exploratory analysis via the bootstrap
procedure, to identify an age-cutpoint at which age-AMH regression lines for cases and
controls intersected. Specifically, 200 bootstrap replicates were sampled. For each such
sample, the full model with the interaction was fitted, and the age cutpoint was computed.
The distribution of the 200 age cutpoints was used to obtain a point-estimate (mean of the
estimates across the 200 samples) and bias-corrected (BCa) 95% confidence interval for the
age cutpoint [21]. In post-hoc analysis, we stratified the sample by women younger than the
age cutpoint estimate and women older than the age cutpoint estimate, and examined the
relationship between breast cancer status and AMH within each stratum.
A priori power calculations were performed based on the sample size of the cohorts to
determine the detectable difference in AMH, the primary outcome of interest, between the
two populations. In healthy women between 30 and 44, the geometric mean (SD) for AMH
was observed to be 1.6 (2.3) ng/mL [22]. With 80% power, alpha error of 0.05, the study is
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powered to detect a difference of at least 0.38 SD in AMH levels between the two
populations.
Results
The study included a total of 207 participants, 108 women with breast cancer and 99 healthy
women without breast cancer. Table 1 summarizes the characteristics of the participants.
The median age of breast cancer participants was 40.2 years (range 28.5 to 44.9). The
majority of breast cancer patients had invasive ductal carcinoma and tumors expressing
estrogen and/or progesterone receptors. Control women had a median age of 33.9 (range
29.3–42.5). Compared to healthy participants, breast cancer participants were significantly
older, less likely to be Caucasian and had higher gravidity. Body size, exposure to cigarette
smoking and regularity of menstrual pattern were similar between the two groups.
Unadjusted AMH, FSH and inhB levels are depicted in Table 1. The geometric mean (SD)
AMH levels were 0.66 (3.5) ng/mL for breast cancer participants and 1.1 (2.9) ng/mL for
controls. In univariate analysis, AMH was significantly lower in breast cancer participants;
more breast cancer participants had AMH levels below assay detection than controls (19%
vs. 7%, p=0.009). AMH was also inversely associated with age (p<0.001) and gravidity
(p=0.03), but was not significantly associated with race and ethnicity (p=0.61), regularity of
menstrual cycles (p=0.33), cigarette smoking (p=0.67), and BMI (p=0.18). Among cancer
characteristics, AMH was not associated with stage (p=0.81) or hormone receptor status
(p=0.35). FSH and inhB were similar between the two groups among the subset of
participants (45 women with breast cancer and 91 healthy women) with estradiol levels less
than 80 pg/mL.
A multivariable linear regression model was constructed to examine the association between
log-transformed AMH levels and cancer status, while controlling for potential confounding.
AMH was not significantly associated with breast cancer status in a model adjusting for age,
gravidity, BMI, race/ethnicity, regularity of menstrual cycles, and cigarette smoking. Table
2 depicts the predicted geometric mean AMH levels from this model. FSH and inhB were no
different by breast cancer status in separate models adjusting for age, gravidity, race,
regularity of menstrual cycles, cigarette smoking and BMI. In the model for FSH, the
geometric mean FSH (95% CI) for breast cancer participants and healthy controls were 7.6
(6.6–8.7) and 7.2 (5.7–8.9) mIU/mL, respectively (p=0.70). In the model for inhB, the
geometric mean inhB for breast cancer participants and healthy controls were 29.4 (24.0–
36.2) and 29.4 (21.5–40.0) pg/mL, respectively (p=0.98).
Figure 1 depicts log-transformed AMH levels graphed by age and breast cancer status. The
curves were observed to intersect, suggesting potential effect modification. In a model
controlling for gravidity, BMI, race, regularity of menstrual cycles and cigarette smoking,
the association between breast cancer and AMH levels differed by age (p-
valueinteraction=0.017). Via bootstrapping resampling, the age (95% CI) at which the
interaction was observed was 37.2 (33.7, 40.6). In post-hoc analysis, AMH levels were not
significantly associated with breast cancer status in women younger than 37 (β=0.24, 95%
CI −0.24, 0.72, p=0.32). However, in women 37 years and older, AMH was significantly
lower in breast cancer patients than in healthy women (β= −0.85, 95% CI −1.48, −0.22,
p=0.009). In a model adjusting for age in addition to the interaction between age 37 and
breast cancer, the association between breast cancer and AMH levels remained significantly
different by age ≥ or < 37 (p-valueinteraction=0.008). In separate models examining FSH and
inhB, no significant interactions between breast cancer status and hormone level were
observed (data not shown).
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This study compared AMH, FSH and inhB, three measures of ovarian reserve, between
young women with newly diagnosed breast cancer and healthy controls without a history of
infertility. The results showed that AMH, FSH and inhB levels did not differ by breast
cancer status. For AMH, exploratory analyses suggest that levels may be lower in breast
cancer patients older than 37 years of age, compared to healthy controls. These findings
support that ovarian reserve, as measured by these biomarkers, is not adversely impacted by
the presence of breast cancer in younger women.
The data contribute to very limited literature examining the impact of cancer on ovarian
reserve measures. Previously, FSH and antral follicle count (AFC) have been reported to be
similar between female patients facing a variety of cancer and autoimmune disease
diagnoses and infertile control women [15, 16, 23–25]. A single small study of 26 newly
diagnosed breast cancer patients between ages 30 and 40 demonstrated similar AMH levels
between cancer patients (0.86 ng/mL, range 0.07–9.1) and women who achieved a
successful birth after IVF for male factor infertility (0.94 ng/mL, range 0.2–7.7) [26].
However, the authors reported that 29% of cancer patients had AMH levels less than the
lower limit of their healthy controls. Moreover, this study did not study breast cancer
patients who are in their early 40s and still of reproductive age. Recently, the European
FertiPROTEKT Network published data comparing AMH levels between 38 Hodgkin
Lymphoma (HL) and Non-Hodgkin Lymphoma (NHL) women prior to cancer treatment and
healthy controls from the community, similar to the design of our study [27]. The mean age
of the cancer and control group was 25.5 years (range 18–33), and lower AMH levels (mean
± SD) were observed in lymphoma patients (2.1 ± 1.5 ng/mL) than healthy controls (3.2 ±
2.2 ng/mL). Of note, lymphomas are the primary cancer type associated with lower sperm
quality in males [7, 8]. Though bound by small sample sizes, generally less than 50
participants with cancer per study, these early data on biochemical and ultrasound measures
of ovarian reserve prior to cancer treatment suggest that cancer may impact ovarian reserve,
but the effect may differ by type of cancer.
A complementary approach to testing if ovarian reserve is diminished by cancer is to
compare ovarian stimulation outcomes between cancer patients undergoing egg and embryo
banking prior to treatment and healthy controls. Several studies have reported that the
number of retrieved eggs, proportions of mature eggs, and fertilization rates among those
who banked embryos have not been found to be different between fertility preservation
cases and infertile controls when all cancers are considered [15–17, 23]. Specifically, when
considering breast cancer patients versus other cancer types, the data are mixed. Two studies
suggest lower numbers of eggs retrieved and higher requirements for medications used to
stimulate the ovaries in breast cancer patients than other cancers [19, 28]. However, in the
FertiPROTEKT Network study, the number of retrieved eggs was higher in breast cancer
than in lymphoma patients [27]. Taken together, there is some evidence that malignancies
may differentially affect ovarian function, but the literature to date has had limited power to
test specific malignancies by pooling diagnoses and reporting small sample sizes. Moreover,
as most young female cancer patients are not infertile, healthy women without a history of
infertility may be a more appropriate comparison group. Choice of infertile controls, even
with tubal factor or male factor diagnoses, does not eliminate the possibility of underlying
ovarian reserve problems, which could bias comparisons with cancer patients toward the
null.
We report the first data to compare ovarian reserve between women with and without breast
cancer in the general population, rather than the infertility population. As most women with
breast cancer do not have a history of infertility, this design allows for a comparison of
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cancer patients and the source population from which they arise. Recruitment of control
participants included both clinics and the community. With this strategy, the control
population of the current study was more representative of the general population and
minimized confounding by indication. Furthermore, one cancer type was targeted, with
results most generalizable to young women with breast cancer. Overall, we did not find
lower AMH levels in breast cancer patients than in healthy controls, suggesting that ovarian
reserve as measured by AMH is generally not adversely impacted by breast cancer. A
strength of the study was the ability to analyze measures in a sizeable population that was
adequately powered to detect smaller differences in AMH, but a type II error cannot be ruled
out for differences in AMH that are smaller. As expected, AMH was inversely associated
with age in the breast cancer population, similar to data reported for the general population.
In exploratory analyses, we found that the relationship between AMH and breast cancer
status may differ by age. In women older than 37 years, AMH was lower than in controls. It
is possible that breast cancer diagnosis impacts ovarian reserve, but to a limited extent, such
that in younger women with ample ovarian reserve, oocyte loss relative to the remaining
cohort is minimal. It is also possible that we did not observe a difference in younger women
because of limited power. However, in women with diminished ovarian reserve, e.g. older
women, this impact would be more significant. Thus, some women may have a
“susceptibility window”. Similar findings have been noted with tobacco use and ovarian
reserve [29]. Such a hypothesis would need to be examined in a larger cohort.
There are several limitations to the study. While control women were drawn from the
general population, it is important to recognize that controls were recruited from a different
geographic region and for studying hormonal predictors of time to pregnancy. As such,
while we are able to adjust for known confounders such as age, there may be additional
unknown differences between the two populations and possible confounding for which we
cannot adjust. It is also possible that higher AMH levels in healthy controls who are over 37
reflect a selection bias in the population of women who attempt natural fecundity at older
reproductive age. Third, the timing of blood draws was in the early follicular phase for
healthy controls, but throughout the menstrual cycle for breast cancer participants. For this
reason, AMH levels were selected as the primary outcome as levels appear to be
independent of gonadotropins and are relatively stable through the menstrual cycle and do
not follow fluctuations seen in FSH and inhB [30–32]. Because of the variability of FSH and
inhB over the menstrual cycle, samples for these comparisons was limited to those with
estradiol levels < 80pg/mL to reflect timing in the early follicular phase. In breast cancer
participants, blood sampling could occur before or after surgery, and it is not known whether
stress related to surgery could impact ovarian reserve. We postulate that this is unlikely to
affect AMH levels significantly as they are normal in women with hypothalamic
amenorrheic women compared to women with amenorrhea due to ovarian failure [33]. Data
on infertility or a history of decreased ovarian reserve prior to cancer diagnosis was not
collected. Therefore, it is possible that if some of the breast cancer participants had
decreased ovarian reserve prior to diagnosis, this would bias the results away from the null.
Breast cancer status in controls was ascertained by self-report only, but as the incidence of
breast cancer is low in this age group, case misclassification is less likely. Another limitation
of the study was that we were unable to compare stimulation outcomes. It may be possible
that cancer impacts ovarian function/response to stimulation and this effect is not reflected
in basal measures of ovarian reserve. Finally, a proportion of both cancer and healthy
participants self-reported menstrual irregularity and are potential patients with polycystic
ovarian syndrome (PCOS). But while PCOS is typically associated with higher AMH levels,
menstrual pattern was not related to AMH in this dataset.
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Importantly, the current study utilizes the new AMH Gen II assay. Until recently, two
ELISA assays (DSL 10–14400 and Immunotech) have been available for commercial use.
The assays use different pairs of monoclonal antibodies and are standardized differently.
The new AMH Gen II assay has been developed by Beckman Coulter using DSL antibodies
but calibrated to the Immunotech assay [34, 35]. Currently, the AMH Gen II assay is the
primary test kit for AMH that is available on the market, with Beckman Coulter as the sole
manufacturer. The assay is highly specific and reproducible, with inter-assay coefficients of
variation between 5.3–7.7% [36]. Several studies have reported conversion factors between
the two assays [30, 37–39], but the conversion factors varied widely. In our dataset, the
healthy participants had AMH levels measured with the DSL assay as well as the Gen II
assay. Using the conversion factors on DSL AMH levels would have resulted in different
associations between AMH and cancer status (data not shown). This finding supports the use
of the same AMH assay among all samples of a study.
In conclusion, the study presents new data on AMH in young breast cancer patients prior to
gonadotoxic treatment. Among the youngest of breast cancer patients, AMH levels did not
differ significantly from those in healthy women of similar age. Exploratory analysis
suggests AMH levels may be lower in older breast cancer patients compared to controls.
Consistent with prior studies, FSH and inhibin B were also not impacted by cancer status.
Altogether, these findings suggest that ovarian reserve as measured by these biomarkers is
generally not adversely impacted by the presence of breast cancer and provide support for
the potential success of fertility preservation strategies prior to institution of cancer
treatment.
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Log-transformed AMH levels (95% CI) by age and cancer status.
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Table 1
Baseline characteristics and hormone measures of ovarian reserve of breast cancer and healthy participants
Breast cancer participants
(N=108) Healthy participants (N=99) p-value
Age, Median (IQR) 40.2 (5.5) 33.0 (4.6) <0.001a
 <35 N(%) 11 (10) 63 (63)
 35–39 N(%) 27 (25) 29 (29)
 >40 N(%) 70 (65) 7 (7)
Race and ethnicity (%) 0.002b
 Caucasian 77 (72) 86 (87)
 African American 13 (12) 5 (5)
 Asian 8 (7) 4 (4)
 Hispanic 9 (8) 0 (0)
 Other 0 (0) 4 (4)
Regular menses (%) 96 (89) 88 (88) 0.96b
Prior pregnancy (%) 72 (67) 58 (59) 0.20b
Gravidity, Median (IQR) 2 (3) 1 (1) <0.001a
BMI, Mean (SD) 25.3 (5.9) 25.1 (5.9) 0.84d
Current cigarette smoking (%) 6 (6) 1 (1) 0.12
Breast cancer type (%)
 Ductal 97 (90)
 Lobular 4 (4) - -
Cancer stage (%) - -
 0 5(5)
 I 33 (30)
 II 50 (46)
 III 19 (18)
Estrogen or progesterone receptor positive (%) 72 (66) - -
BRCA status (%)
 Positive 10 (9) - -
 Negative 38 (36)
 Unknown 59 (55)
AMH (ng/ml), Geometric mean (SD) 0.66 (3.5) 1.1 (2.9) <0.001d
AMH below limit of detectability (<0.17 ng/mL), n (%) 21 (19) 7 (7) 0.009b
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Breast cancer participants
(N=108) Healthy participants (N=99) p-value
FSH (mIU/ml), Geometric mean (SD)e 7.7 (2.4) 7.3 (1.5) 0.52d










Restricted to participants with estradiol levels ≤ 80 pg/mL(45 breast cancer and 91 healthy participants)
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Table 2
Adjusted geometric mean values of AMH (ng/mL)a
Characteristic AMH (95% CI) p-value
Breast Cancer status 0.60
 Affected 0.85 (0.66–1.09)
 Unaffected 0.76 (0.58–0.98)
Age <0.001
 <35 1.46 (1.08–1.97)
 35–39 1.02 (0.76–1.38)
 >40 0.37 (0.27–0.50)
BMI 0.37
 <18.5 1.72 (0.64–4.65)
 18.5–24.9 0.83 (0.68–1.02)
 25.0–29.9 0.72 (0.53–1.0)
 >30 0.70 (0.46–1.07)
Prior pregnancy 0.57
 0 0.75 (0.57–0.99)
 ≥ 1 0.83 (0.68–1.0)
Race/ethnicity 0.42
 Caucasian 0.78 (0.65–0.92)
 Non-Caucasian 0.92 (0.64–1.3)
Regular menses 0.56
 Yes 0.82 (0.69–0.96)
 No 0.70 (0.43–1.13)
Current cigarette smoking 0.54
 Yes 0.59 (0.22–1.58)
 No 0.81 (0.69–0.95)
a
As predicted by linear regression models with log-transformed AMH as the outcome, and breast cancer status, age, gravidity, race, BMI,
regularity of menstrual cycles, and cigarette smoking as predictor variables (R2=0.21)
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